Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Regeneron Pharmaceuticals, Inc.
REGN
$923.34
Name : Regeneron Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $95,517,548,544.00
EPSttm : 45.24
finviz dynamic chart for REGN
Regeneron Pharmaceuticals, Inc.
$923.34
2.35%
$22.19
REGN — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.23

Margin Of Safety %

23

Put/Call OI Ratio

0.96

EPS Next Q Diff

-2.54

EPS Last/This Y

24.7

EPS This/Next Y

-6.89

Price

923.34

Target Price

995.27

Analyst Recom

1.77

Performance Q

10.71

Upside

-36.2%

Beta

0.09

Ticker: REGN




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-10-21REGN806.050.822.7535434
2026-10-22REGN819.60.832.6135683
2026-10-23REGN805.40.863.2036495
2026-10-26REGN807.990.903.6636193
2026-10-27REGN816.060.910.5436484
2026-10-28REGN813.660.910.3736734
2026-10-29REGN817.430.900.6737313
2026-10-30REGN927.910.900.4539209
2026-11-02REGN961.70.910.7238641
2026-11-03REGN974.430.940.5140561
2026-11-04REGN930.760.961.4940705
2026-11-05REGN902.820.990.6441682
2026-11-06REGN904.381.000.3742002
2026-11-09REGN920.371.020.5039572
2026-11-10REGN916.281.010.3840071
2026-11-11REGN959.611.000.4140549
2026-11-12REGN951.770.990.6441026
2026-11-13REGN955.660.991.4241378
2026-11-16REGN952.790.990.9640655
2026-11-17REGN957.370.970.2740653
2026-11-18REGN945.60.970.4040767
2026-11-19REGN923.370.960.2841015
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-10-21REGN807.5435.8632.857.84
2026-10-22REGN819.5436.1539.458.46
2026-10-23REGN805.1836.1329.558.46
2026-10-26REGN807.5737.0454.558.61
2026-10-27REGN815.9536.9497.358.85
2026-10-28REGN813.6036.9416.958.85
2026-10-29REGN817.1236.9464.058.85
2026-10-30REGN927.6637.31238.158.93
2026-11-02REGN961.3237.3142.158.93
2026-11-04REGN930.90124.4-340.768.04
2026-11-05REGN902.91124.4-257.968.68
2026-11-06REGN904.38121.1732.768.68
2026-11-09REGN920.27122.0843.668.75
2026-11-10REGN916.25122.0693.368.75
2026-11-11REGN959.45122.01049.968.75
2026-11-12REGN951.74122.0666.068.75
2026-11-13REGN955.80122.0754.868.75
2026-11-16REGN952.78122.0691.768.75
2026-11-17REGN957.38122.0757.469.01
2026-11-18REGN945.38122.0631.969.01
2026-11-19REGN923.34122.0558.969.01
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-10-21REGN-0.22-0.392.17
2026-10-22REGN-0.22-0.392.17
2026-10-23REGN-0.22-0.392.17
2026-10-26REGN-0.22-0.692.17
2026-10-27REGN-0.22-0.692.15
2026-10-28REGN-0.22-0.692.15
2026-10-29REGN-0.22-0.692.15
2026-10-30REGN-0.22-0.692.15
2026-11-02REGN-0.22-1.172.15
2026-11-03REGN-0.29-1.172.15
2026-11-05REGN-1.15-1.172.14
2026-11-06REGN-1.44-1.172.14
2026-11-09REGN-1.44-0.242.14
2026-11-10REGN-1.44-0.242.14
2026-11-11REGN-1.44-0.242.23
2026-11-12REGN-1.44-0.242.23
2026-11-13REGN-1.44-0.242.23
2026-11-16REGN-1.440.592.23
2026-11-17REGN-1.440.592.23
2026-11-18REGN-1.440.592.23
2026-11-19REGN-1.630.592.23
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS​

18.43

Avg. EPS Est. Current Quarter

25.39

Avg. EPS Est. Next Quarter

15.89

Insider Transactions

-1.63

Institutional Transactions

0.59

Beta

0.09

Average Sales Estimate Current Quarter

5852

Average Sales Estimate Next Quarter

4600

Fair Value

1137.57

Quality Score

98

Growth Score

89

Sentiment Score

92

Actual DrawDown %

23.8

Max Drawdown 5-Year %

-59.7

Target Price

995.27

P/E

20.38

Forward P/E

13.02

PEG

0.64

P/S

5.65

P/B

2.85

P/Free Cash Flow

24.96

EPS

45.3

Average EPS Est. Cur. Y​

69.01

EPS Next Y. (Est.)

62.12

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

28.51

Relative Volume

0.88

Return on Equity vs Sector %

-12.2

Return on Equity vs Industry %

6.6

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

11.38

EBIT Estimation

558.9
◆ REGN Healthcare
$923.34
📉
Swing / Pullback
Buy the dip on strong trends
29 /100
WEAK
Trend
0/20
Pullback
2/25
Volume
7/15
Valuation
13/20
TP/AR
4/10
Options
3/10
RSI
58
Range 1M
67.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
51 /100
WEAK
Momentum
5/25
Growth
23/30
Estimates
10/20
Inst/Vol
6/15
Options
7/10
EPS Yr
54%
EPS NY
3.9%
52W%
83.8%
💎
Long-Term Value
Quality companies, undervalued
60 /100
WATCH
🟡 HOLD +2.3% upside
Quality
20/30
Valuation
11/30
Growth
18/25
Stability
10/10
LT Trend
1/5
Upside
+2.3%
Quality
98
MoS
23%
REGN — P/E HistoricalBiotechnology
Regeneron Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 15410
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
REGN

Latest News

—
Caricamento notizie per REGN…
stock quote shares REGN – Regeneron Pharmaceuticals, Inc. Stock Price stock today
news today REGN – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch REGN – Regeneron Pharmaceuticals, Inc. yahoo finance google finance
stock history REGN – Regeneron Pharmaceuticals, Inc. invest stock market
stock prices REGN premarket after hours
ticker REGN fair value insiders trading